Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501091 | 0.86 | HTR7 (0.48) | HTR7MEN1KMT2AMGLL | |
| SCHEMBL6504218 | 0.85 | HTR7 (0.47) | HTR7MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL6075954 | 0.84 | KMT2A (0.53) | HTR7MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6501083 | 0.82 | HTR7 (0.46) | HTR7MEN1KMT2AALDH1A1CHRM4 | |
| SCHEMBL6493038 | 0.82 | BACE1 (0.46) | HTR7 | |
| SCHEMBL6075908 | 0.81 | KMT2A (0.48) | HTR7MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6498974 | 0.80 | KMT2A (0.47) | HTR7MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6492092 | 0.80 | HTR7 (1.00) | HTR7MEN1KMT2ADRD2 | |
| SCHEMBL6493917 | 0.80 | RAB9A (0.46) | HTR7MAPTALDH1A1NPSR1CHRM4 | |
| Hydrochloric Acid SCHEMBL6490630 | 0.79 | HTR7 (0.98) | HTR7MEN1KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | HTR7 1189/4885MEN1 3540/4885KMT2A 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.